MDMA is not the same as Ecstasy. Substances sold on the street under the name Ecstasy do sometimes contain MDMA, but more often contain ketamine, caffeine, BZP, and other narcotics and stimulants. In laboratory studies, pure MDMA—but not Ecstasy—has been proven sufficiently safe for human consumption when taken a limited number of times in moderate doses.
MDMA-assisted psychotherapy is currently illegal outside of the context of FDA-reviewed studies.
We are currently only seeking subjects for one Phase 2 study of MDMA-assisted psychotherapy for U.S. veterans with chronic, treatment-resistant PTSD resulting from service. Click here for more information if you think you may qualify.
Make a donation to help make MDMA-assisted psychotherapy a legal treatment option for people suffering from PTSD.
MDMA’s risk profile is low enough to justify further explorations in clinical trial settings. However, this only applies to carefully designed research contexts with screened adult subjects, and does not apply to any other use of MDMA.
MDMA has been administered to more than 750 human subjects in clinical studies with only one single serious adverse event occurring as a result of the drug.
MDMA can increase body temperature and heart rate, but these effects are temporary. MDMA may also produce modest changes in immune functioning, lasting up to 48 hours.
Other spontaneously reported reactions and common adverse effects include:
These effects are transient and diminish as drug effects wane.
Further information on the risks associated with MDMA, including information drawn from case reports and studies of illicit Ecstasy users, can be found in the sponsor’s Investigator's Brochure (pdf).